Response from DrT
In order to be able to measure the cardioprotective effect is why we are running the first trial - this data will will be used to construct the synthetic control arm.
Preventing cardiac damage from chemotherapy is not something that is likely to have a placebo effect. We are measuring the actual function of the heart which is not the sort of thing that responses to a placebo.
As an aside placebo effects outside of pain perception are rare. Most of what is called the placebo effect is really just regression to the mean. Many diseases cycle up and down in severity and patients tend to undertake treatment (or enter a trial) when they are feeling most unwell. If you start monitoring a patient when they are at their worst and they naturally get better as their disease cycles back down then you are going to see an improvement from whatever treatment you give the patient.
- Forums
- ASX - By Stock
- RAC
- Ann: Ethics submission to commence cardioprotection trial
Ann: Ethics submission to commence cardioprotection trial, page-25
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.78 |
Change
-0.040(2.20%) |
Mkt cap ! $302.5M |
Open | High | Low | Value | Volume |
$1.81 | $1.82 | $1.76 | $132.8K | 74.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 170 | $1.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.78 | 2 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 1.755 |
3 | 12714 | 1.750 |
1 | 3000 | 1.740 |
1 | 1405 | 1.720 |
4 | 25414 | 1.700 |
Price($) | Vol. | No. |
---|---|---|
1.780 | 3781 | 1 |
1.830 | 7500 | 1 |
1.840 | 1000 | 1 |
1.850 | 5222 | 1 |
1.880 | 2351 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |